Allogeneic Hematopoietic Cell Transplantation

Allogeneic hematopoietic cell transplantation (HCT) has been firmly integrated in the treatment algorithm of acute myeloid leukemia (AML) patients. Optimization of donor choice, supportive care, conditioning regimens, and monitoring of residual disease have led to a constant improvement of outcomes. Specifically, more and more patients at higher ages are offered allogeneic HCT as the therapeutic option with the highest curative potential.